HR and breast cancer: Additionally, antiangiogenic drugs like bevacizumab have shown potential efficacy on advanced BC <i>via</i> inhibiting pathological neovascularizationits.<h4>Case presentation</h4>Here, we will share our experience in treating a 49-year-old woman initially diagnosed with stage IV breast cancer characterized by hormone receptor (HR)-negativity and HER2-positivity.